Menu

HealthTech Member:

electronRx

 

Dr Bipin Patel - Founder and CEO talks to us about electronRx.

Tell us about electronRx.

electronRx is an interdisciplinary team of world class bioelectronic engineering and scientific talent. We are a deep tech company leading the development of first-in-class digital medicines that transform the treatment of chronic diseases, innovating the areas of remote diagnostics and pain management. Our fundamental goal is the democratisation of digital therapeutics; placing advanced, evidence-based solutions at the heart of modern healthcare to alleviate human suffering.
 

How long have you been an Eagle Labs member?

2.5 years.
 

When did you start your business?

October 2017.
 

What's been your biggest highlight?

Our biggest highlight has been building out such a fantastic team of multidisciplinary deep tech engineers and watching the team's creativity and expertise combine and grow. These two factors of being both experts at what we do and having such a wide range of perspectives synthesising to enable the most creative responses to challenges is allowing us to address the big problems, solving which would make waves globally - that is what's really exciting! Our team is fast-growing and agile which has allowed us to make progress very quickly and has led to some outstanding achievements.
 

What's been your biggest challenge?

Similar to many companies, our biggest challenge has been adapting to the new realities of work in an increasingly remote environment. Maintaining momentum is even more top of mind now than it was before the pandemic hit - we need to keep solving the problems that we are working on while pivoting within the business plan to accommodate for COVID-19 interruptions. From one lockdown into another... and into another! The obstacles continue to exist and we are continually adapting to overcome them and grow.
 

Advice for entrepreneurs starting out

Develop resilience! And make sure you are always pursuing your passion - don't let yourself be blown off track.

 

Share this page

Go back to the top of the page